You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 4, January 30, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  This Week in JAMA
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

This Week in JAMA

JAMA. 2008;299(4):385.

Drug-Eluting Stents in Routine Clinical Practice

Regulatory approval of currently available drug-eluting coronary stents was granted on the basis of results from relatively small clinical trials that enrolled highly selected patients. To assess outcomes in patients who are representative of "real world" clinical practice, investigators from the 5-center Danish Organization on Randomized Trials with Clinical Outcome (SORT OUT II) study randomly assigned 2098 patients undergoing primary coronary intervention to receive either sirolimus-eluting or paclitaxel-eluting stents to treat target lesions. Galløe and colleagues (SEE ARTICLE) report that there were no significant differences in the composite clinical end point of either cardiac death, acute myocardial infarction (AMI), target lesion revascularization, or target vessel revascularization, or the secondary end points of total and cardiac mortality, AMI, or stent thrombosis among patients receiving either the sirolimus-eluting or paclitaxel-eluting stent. In an editorial, Mukherjee and Moliterno (SEE ARTICLE) discuss the contributions and limitations of the SORT OUT II trial results for determining safe and effective revascularization practices.


Secondhand Smoke and Cystic Fibrosis Lung Disease

Gene-environment interactions are a possible explanation for the variations in disease expression in single-gene disorders, such as cystic fibrosis. The US Cystic Fibrosis Twin and Sibling Study assessed the relationship of 2 environmental factors—secondhand smoke exposure and household socioeconomic status—on lung function in patients with cystic fibrosis. Collaco and colleagues report that participants who were exposed to any secondhand smoke in the home had significantly worse cross-sectional and longitudinal lung function compared with study participants who were never exposed, and this association was not confounded by socioeconomic status. The authors also report that several cystic fibrosis gene variants amplify the association of secondhand smoke exposure with reduced lung function.

(SEE ARTICLE)


MicroRNA Expression and Colon Adenocarcinoma

MicroRNAs—noncoding RNA molecules that regulate the translation of genes—may function as diagnostic biomarkers and therapeutic targets in cancer. Schetter and colleagues examined microRNA expression patterns in colon tumors and paired nontumorous tissue from 2 independent cohorts of patients with sporadic colon adenocarcinoma. The authors identified expression patterns that were associated with colon tumor formation, response to chemotherapy, and cancer-specific survival. In particular, tumors with a high expression of microRNA miR-21 were associated with a poor response to adjuvant chemotherapy and poor patient survival.


Figure 80000FA

(SEE ARTICLE)


CLINICIAN'S CORNER
Eosinophilia in a South American Patient

Mr R, a 49-year-old man from Guyana, has had asymptomatic eosinophilia for at least 1 year, and multiple stool evaluations were negative for ova and parasites. Page and Zenilman discuss the evaluation of patients with eosinophilia, including aspects of the patient history and physical examination, and diagnostic studies that may reveal the cause. The authors highlight the diagnosis and treatment of strongyloidiasis.

(SEE ARTICLE)


Medical News & Perspectives

Researchers report advances in diagnosing and treating red blood cell diseases, although many patients are not receiving a treatment that can significantly reduce morbidity and mortality.

(SEE ARTICLE)


Commentaries

Patient safety and systems of care

(SEE ARTICLE)

Health of contingent workers

(SEE ARTICLE)

Genetics in pediatric primary care

(SEE ARTICLE)


Readers Respond

How would you manage a 32-year-old woman with a 1-year history of chronic abdominal pain? Go to www.jama.com to read the case and submit your response. Your response may be selected for online publication. Submission deadline is January 30.


Author in the Room Teleconference

Join Mark J. Pletcher, MD, February 20, 2008, from 2 to 3 PM eastern time to discuss opioid prescribing by race/ethnicity. To register, go to http://www.ihi.org/AuthorintheRoom.


Audio Commentary

Dr DeAngelis summarizes and comments on this week's issue. Go to http://jama.ama-assn.org/misc/audiocommentary.dtl.


JAMA Patient Page

For your patients: Information about myocardial infarction.

(SEE ARTICLE)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.